Akeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer
I'm PortAI, I can summarize articles.
Akeso Inc. announced a 100% R0 resection rate in its Phase II study of cadonilimab for resectable gastric cancer, presented at the 2025 ESMO Asia Congress. The study showed significant tumor and nodal downstaging, with a 28.6% pCR rate and 71.4% MPR rate. Safety findings were consistent with known profiles. A Phase III trial is ongoing.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments